Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
BioNJ's Prestigious Speaker Roster for Its 12th Annual C-Suite Summit
BioNJ's 12th C-Suite Summit, on Oct. 10, 2024, at Bridgewater Marriott, convenes life sciences executives to discuss critical issues in innovation, policy, and market access. Featuring world-class speakers, the agenda includes topics on AI, talent, and R&D in mental health. Registration is $695 for BioNJ Members, $895 for non-members, and closed to media.
J&J Discontinues Phase II Dengue Study as it Retreats from Infectious Disease
Johnson & Johnson halted Phase II study of antiviral mosnodenvir for dengue prevention due to strategic reprioritization, not safety issues. The company is analyzing the study and will share findings with participants and the scientific community. Mosnodenvir is a pan-serotype inhibitor of the NS4B protein used by dengue viruses for replication.
Global Drug Device Combination Products Market is expected
The Global Drug Device Combination Products Market is projected to reach USD 174.4 billion in 2024 and USD 389.7 billion by 2033 at a CAGR of 9.3%. The US market is expected to grow from USD 59.1 billion in 2024 to USD 125.6 billion by 2033 at a CAGR of 8.7%. Key drivers include technological advancements and rising chronic diseases. Major players include Medtronic, Abbott Laboratories, and Boston Scientific.
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
Galapagos NV appoints Oleg Nodelman as Non-Executive Non-Independent Director, effective October 7, 2024, replacing Dan G. Baker. Nodelman, Founder and Portfolio Manager of EcoR1 Capital LLC, brings expertise in biotech and shareholder value, aligning with Galapagos' strategy to accelerate innovation and create value.
J&J Backs Down From 340B Rebates, But Maintains They're 'Legally Permissible' Per Statute
Johnson & Johnson proposed changes to the 340B drug discount program, but backed down after HRSA deemed them inconsistent with the statute. The 340B program, established in 1992, aims to help underserved communities by allowing eligible hospitals and clinics to purchase outpatient prescription medications at discounts. Recent regulatory developments include FDA approvals for Exact Sciences' Cologuard Plus, Partners Fresenius Kabi and Formycon's Otulfi, Eli Lilly's Retevmo, Sanofi and Regeneron's Dupixent, Bristol Myers Squibb's Cobenfy, and others. Additionally, Pfizer withdrew Oxbryta from the market due to safety concerns.
EU: The Johnson and Johnson vaccine has a possible link with blood clotting
EMA identified a possible link between Johnson & Johnson vaccine and rare deep vein blood clots, recommending it as a side effect. Immune thrombocytopenia also added as an adverse reaction. Johnson & Johnson supports awareness for prompt identification and treatment of rare events.
Nondisclosure: COVID vaccine ad blitz sidestepped transparency rules
Pfizer funded COVID-19 vaccine ads omitted typical disclaimers about risks and FDA approval status, exploiting a loophole to present them as public service announcements. This allowed them to avoid required disclosures under Emergency Use Authorization, despite explicit warnings mandated for such ads.
FDA News Month in Review: September 2024
September 2024 FDA updates include approvals for Embecta's tubeless patch pump for diabetes, Travere Therapeutics' sparsentan for IgA nephropathy, Johnson & Johnson's guselkumab for ulcerative colitis, and the first over-the-counter hearing aid software device. Other approvals cover treatments for conditions like chronic rhinosinusitis with nasal polyps, atopic dermatitis, eosinophilic granulomatosis with polyangiitis, Niemann-Pick disease type C, and schizophrenia. The FDA also issued warnings and accepted NDAs for various treatments, including delgocitinib cream for chronic hand eczema and roflumilast foam for psoriasis.
FDA Receives Application to Review D-VRd in Multiple Myeloma Subset
Johnson & Johnson submitted an FDA application for Darzalex Faspro-based D-VRd regimen to treat newly diagnosed multiple myeloma patients ineligible for transplant, based on CEPHEUS study results showing 60.9% MRD-negativity and 43% risk reduction for progression or death.
© Copyright 2025. All Rights Reserved by MedPath